Physician profile
Peter John Burrows
NPI 1609876523
$9,752.11
in general payments reported to CMS, 2019-2025
34 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $1,058 · 2021: $912 · 2022: $2,486 · 2023: $1,130 · 2024: $1,934 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,197 · Travel and Lodging: $969 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,196.90 |
| Travel and Lodging | $968.84 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $3,600.09 | 2021-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $1,249.09 | 2022-2025 | Aquabeam System |
| Neotract INC. | $1,190.96 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $575.66 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $434.01 | 2019-2025 | |
| Astellas Pharma US INC | $425.75 | 2019-2025 | Xtandi, Myrbetriq |
| Myovant Sciences INC. | $279.41 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $217.55 | 2019-2022 | |
| Janssen Biotech, INC. | $206.23 | 2019-2024 | Erleada |
| Boston Scientific Corporation | $191.85 | 2019-2025 | Ams 700 |
| Axonics, INC. | $187.48 | 2020-2024 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $170.45 | 2019-2025 | |
| Endo USA, INC. | $158.35 | 2024-2025 | Xiaflex, Aveed |
| Antares Pharma, INC. | $155.69 | 2019-2020 | |
| Urogen Pharma, INC. | $121.83 | 2023 | Jelmyto |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $99.46 | 2023-2025 | Eligard, Jatenzo |
| Clarus Therapeutics INC. | $89.15 | 2021 | |
| Valencia Technologies Corporation | $54.06 | 2025 | Ecoin Device Kit |
| Accord Healthcare, INC. | $37.17 | 2024-2025 | |
| Hollister Incorporated | $35.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.16 | 2024 | |
| Medtronic, INC. | $27.75 | 2022 | |
| Cook Medical LLC | $27.02 | 2024 | Cook |
| Laborie Medical Technologies Corp. | $21.56 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Coloplast Corp | $21.34 | 2022 | |
| Dornier Medtech America, INC | $20.74 | 2020 | |
| Acerus Pharmaceuticals Corporation | $19.34 | 2022 | |
| Olympus America INC. | $18.06 | 2025 | Itind System |
| Kowa Pharmaceuticals America, INC. | $17.60 | 2023 | Seglentis |
| Abbvie INC. | $17.39 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $14.61 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.44 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.14 | 2021 | |
| Srs Medical Systems, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Burrows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.